0000000000930716

AUTHOR

Andrea Di Bernardo

0000-0001-5311-8019

showing 3 related works from this author

Humoral immunotherapy of multiple myeloma: perspectives and perplexities

2010

IMPORTANCE OF THE FIELDS Multiple myeloma (MM) is a hematological malignancy still remaining incurable despite the various therapies available, mainly because of the high fraction of refractory/relapsing cases. Therefore, the development of novel therapeutic approaches is urgently needed to overcome conventional treatment resistance. AREAS COVERED IN THIS REVIEW: In the era of targeted therapies, treatments combining a high specificity for neoplastic cells and the capability to interfere with environmental signals should be regarded as the weapons of choice. Monoclonal antibody (mAb)-based humoral immunotherapy could satisfy both these requirements when applied to MM. Indeed, many of the mo…

medicine.drug_classmedicine.medical_treatmentClinical BiochemistryCD38Monoclonal antibodyAntigens NeoplasmDrug DiscoverymedicineAnimalsHumansMultiple myelomamultiple myeloma; immunotherapyPharmacologyCD40biologybusiness.industryConventional treatmentAntibodies MonoclonalImmunotherapymedicine.diseaseImmunity Humoralmultiple myelomamultiple myeloma humoral immunotherapyHematological malignancyImmunologyMolecular targetsbiology.proteinimmunotherapybusiness
researchProduct

CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis

2008

Abstract CD146+ bone marrow stromal cells have been recently recognized as clonogenic osteoprogenitors able to organize a complete hematopoietic microenvironment. In this study we used immunohistochemical analysis to investigate the contribution of CD146+ bone marrow osteoprogenitors to the stromal remodeling occurring in the different stages of primary myelofibrosis. We found that CD146+ cells sited at the abluminal side of the bone marrow vessels and branching among hematopoietic cells significantly increased in the advanced stages of primary myelofibrosis (p<0.001), paralleling the extent of fibrosis (r=0.916, p<0.0001) and the microvascular density (r=0.883, p<0.0001). Coherently with a…

AdultMalebone marrow stromal cellmedicine.medical_specialtyPathologyStromal cellAngiogenesisBone Marrow CellsCD146 AntigenBiologyMural cellInternal medicinemedicineHumansMyelofibrosisAgedCell ProliferationNeoplasm StagingAged 80 and overHematologyCD146; bone marrow stromal cells; primary myelofibrosisStem CellsHematologyMiddle Agedmedicine.diseaseHaematopoiesismedicine.anatomical_structureCD146Primary MyelofibrosisBrief ReportsFemaleBone marrowStem cell
researchProduct

Ki-67 immunoexpression and radiological assessment of necrosis improves accuracy of conventional and modified core biopsy systems in predicting the f…

2021

Based on the French Federation Nationale des Centers de Lutte Contre le Cancer (FNCLCC) grading system, this study assesses the accuracy of conventional and modified core biopsy (CB) systems in predicting the final grade (low vs high) assigned to the resected specimen. Substituting Ki-67 immunoexpression for mitotic count, and radiological for histological assessment of necrosis, we used two modified FNCLCC CB grading systems: (1) Ki-67 immunoexpression alone, and (2) Ki-67 plus radiological assessment of necrosis. We graded 199 soft tissue sarcomas (STS) from nine centers, and compared the results for the conventional (obtained from local histopathology reports) and modified CB systems wit…

AdultMalemedicine.medical_specialtySoft Tissue NeoplasmsPathology and Forensic MedicineRadiological necrosisNecrosisCore biopsymedicineBiomarkers TumorHumansGrading (education)Retrospective StudiesNot evaluatedReceiver operating characteristicbiologybusiness.industrySarcomasSoft tissueSarcomaCell Biologymedicine.diseaseKi-67 AntigenRadiological weaponKi-67biology.proteinKi-67HistopathologyFemaleSarcomaBiopsy Large-Core NeedleNuclear medicinebusinessFNCLCC grading system
researchProduct